ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

REVLIMID
Anemias
Leukemias, lymphomas, and other hematologic cancers
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

REVLIMID Rx

Generic Name and Formulations:
Lenalidomide 2.5mg, 5mg, 10mg, 15mg, 25mg; caps.

Company:
Celgene Corp

e-Prescribe this drug via Surescripts


Therapeutic Use:

Indications for REVLIMID:

Transfusion-dependent anemia due to Low- or Intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality.

Adult Dose for REVLIMID:

Do not break, chew, or open caps. Swallow whole with water. ≥18yrs: initially 10mg per day; adjust dose based on response. Renal impairment: Moderate (CrCL 30-60mL/min): 5mg per day. Severe (CrCL <30mL/min without dialysis): 2.5mg per day. ESRD (CrCL <30mL/min with dialysis): 2.5mg once daily; administer after dialysis (on dialysis days). Dose adjustments if thrombocytopenia or neutropenia develops: see literature.

Children's Dose for REVLIMID:

<18yrs: not recommended.

Pharmacological Class:

Immunomodulator.

Contraindications:

Pregnancy (Cat. X). Women who may become pregnant.

Warnings/Precautions:

Must register patient in RevAssist program; patient must understand toxicity with fetal exposure. Counsel patient on need for contraception; female: use 2 forms of contraception 1 month before, during, and 1 month after therapy; male: use condom during and 1 month after therapy; obtain 2 negative pregnancy tests (one within 10–14 days, and then another within 24 hours prior to starting therapy), repeat at least weekly for 1st month then every 4 weeks; get informed consent. Monitor for signs/symptoms of thromboembolic events. Obtain CBCs weekly for first 8 weeks, then monthly. Renal impairment (monitor). Monitor for tumor lysis syndrome in those with high tumor burden. Maximum 1 month per ℞. Nursing mothers: not recommended.

Interactions:

Monitor digoxin. Concomitant warfarin; monitor PT, INR. May increase risk of thrombosis with erythropoietic agents or estrogen containing therapies.

Adverse Reactions:

Birth defects, thrombocytopenia, neutropenia, GI upset, pruritus, rash, fatigue, arthralgia, pyrexia, back pain, cough, dizziness, headache, dyspnea, blurred vision, muscle cramp; thrombosis/embolism, allergic reactions (discontinue if occurs; do not resume), tumor flare reaction, hepatotoxicity.

Note:

Available only through RevAssist program. Report any suspected fetal exposure to the FDA at (800) FDA-1088 and Celgene at (888) 423-5436.

How Supplied:

Caps 2.5mg, 5mg, 10mg—28, 100
15mg, 25mg—21, 100

Indications for REVLIMID:

Multiple myeloma (in combination with dexamethasone) in patients who have received at least one prior therapy.

Adult Dose for REVLIMID:

Do not break, chew, or open caps. Swallow whole with water. ≥18yrs: initially 25mg once daily on Days 1–21 of each 28-day cycle. Renal impairment: Moderate (CrCL 30-60mL/min): 10mg per day. Severe (CrCL <30mL/min without dialysis): 15mg every 48 hrs. ESRD (CrCL <30mL/min with dialysis): 5mg once daily; administer after dialysis (on dialysis days). Dose adjustments if thrombocytopenia or neutropenia develops: see literature.

Children's Dose for REVLIMID:

<18yrs: not recommended.

Pharmacological Class:

Immunomodulator.

Contraindications:

Pregnancy (Cat. X). Women who may become pregnant.

Warnings/Precautions:

Must register patient in RevAssist program; patient must understand toxicity with fetal exposure. Counsel patient on need for contraception; female: use 2 forms of contraception 1 month before, during, and 1 month after therapy; male: use condom during and 1 month after therapy; obtain 2 negative pregnancy tests (one within 10–14 days, and then another within 24 hours prior to starting therapy), repeat at least weekly for 1st month then every 4 weeks; get informed consent. Monitor for signs/symptoms of thromboembolic events. Obtain CBCs every 2 weeks for first 3 months, then monthly. Renal impairment (monitor). Monitor for tumor lysis syndrome in those with high tumor burden. Monitor for second primary malignancies. Maximum 1 month per ℞. Nursing mothers: not recommended.

Interactions:

Monitor digoxin. Concomitant warfarin; monitor PT, INR. May increase risk of thrombosis with erythropoietic agents or estrogen containing therapies.

Adverse Reactions:

Birth defects, thrombocytopenia, neutropenia, GI upset, pruritus, rash, fatigue, arthralgia, pyrexia, back pain, cough, dizziness, headache, dyspnea, blurred vision, muscle cramp; thrombosis/embolism, allergic reactions (discontinue if occurs; do not resume), tumor flare reaction, hepatotoxicity.

Note:

Available only through RevAssist program. Report any suspected fetal exposure to the FDA at (800) FDA-1088 and Celgene at (888) 423-5436.

How Supplied:

Caps 2.5mg, 5mg, 10mg—28, 100
15mg, 25mg—21, 100